|
Press Releases |
|
|
|
Thursday, September 28, 2023 |
|
Tokio Marine Nichido and Eisai Co-Develop Industry's First "Dementia Care Support Insurance" |
Tokio Marine & Nichido Fire Insurance Co., Ltd. and Eisai Co., Ltd. announced that they have co-developed "Dementia Care Support Insurance" to financially support early detection and early treatment for dementia as a part of their business alliance for the realization of a Dementia Inclusive Society. more info >> |
|
Monday, September 25, 2023 |
|
"LEQEMBI Intravenous Infusion" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Japan |
Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" Intravenous Infusion (200 mg, 500mg, lecanemab) has been approved in Japan as a treatment for slowing progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease (AD). more info >> |
|
Thursday, September 21, 2023 |
|
Eisai: Release of Dementia Disease Awareness Videos for World Alzheimer's Day, September 21 |
Eisai Co., Ltd. announced today on World Alzheimer's Day, that it has released a dementia awareness video, "Life Goes On 2023: Two Memories, One Story", on its dementia information website "Sodan.e-65" and YouTube, which are intended to deepen the understanding of dementia. more info >> |
|
Tuesday, September 12, 2023 |
|
Eisai Establishes Theoria Technologies Co., Ltd., A New Digital Business Company To Build A Dementia Ecosystem |
Eisai Co., Ltd. announced today that it has established a digital business company Theoria technologies Co., Ltd. ("Theoria technologies") which will accelerate the development of a dementia ecosystem. Theoria technologies is a wholly owned subsidiary of Eisai. more info >> |
|
Thursday, July 20, 2023 |
|
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023(AAIC2023)において発表 |
エーザイ株式会社とバイオジェン・インクは、このたび、アルツハイマー病(AD)治療剤レカネマブ(一般名、米国ブランド名:「LEQEMBI」)について、臨床第III相Clarity AD試験におけるレカネマブ投与によるアミロイドベータ(Aβ)の減少とパスウェイにおける下流のバイオマーカー変化の解析結果、ならびに現在開発中の皮下投与製剤に関する最新知見をアルツハイマー病協会国際会議2023において、発表したことをお知らせします。 more info >> |
|
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 |
Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes. more info >> |
|
Wednesday, July 12, 2023 |
|
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research |
Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
Friday, July 7, 2023 |
|
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI more info >> |
|
エーザイとバイオジェン・インク、「LEQEMBI(R)」(レカネマブ)がアルツハイマー病治療薬として米国FDAよりフル承認を取得 |
エーザイ株式会社(本社:東京都、代表執行役CEO:内藤晴夫、以下 エーザイ)とバイオジェン・インク(Nasdaq:BIIB、本社:米国マサチューセッツ州ケンブリッジ、CEO:Christopher A. Viehbacher、以下 バイオジェン)は、このたび、米国食品医薬品局(FDA)が「LEQEMBI(R)」注射100 mg/mL溶液(一般名:レカネマブ)について、フル承認に向けた生物製剤承認一部変更申請(supplemental Biologics License Application:sBLA)を承認したことをお知らせします。 more info >> |
|
Friday, June 30, 2023 |
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
InfoComm India 2024 Wraps Up with Impressive 17% Increase in Unique Attendance
Sept 9, 2024 23:30 HKT/SGT
|
|
|
Inaugural Hong Kong Shopping Festival ends successfully
Sept 9, 2024 19:03 HKT/SGT
|
|
|
Zhong An Group(0672.HK) Seeks Sustainable Development
Sept 9, 2024 18:43 HKT/SGT
|
|
|
首届「香港好物节」圆满结束
Sept 9, 2024 18:33 HKT/SGT
|
|
|
首屆「香港好物節」圓滿結束
Sept 9, 2024 18:02 HKT/SGT
|
|
|
Kincora Secures New Strategic Ground On Australia's Premier Porphyry Copper-Gold Province
Sept 9, 2024 17:39 HKT/SGT
|
|
|
眾安集團(0672.HK):精耕穩進 扎牢底盤 謀持久發展
Sept 9, 2024 17:38 HKT/SGT
|
|
|
Korea Continues to Lead the Charge in Shaping the Future of Streaming in Asia
Sept 9, 2024 17:37 HKT/SGT
|
|
|
DENSO to Build a New Plant at the Zenmyo Plant
Sept 9, 2024 17:15 JST
|
|
|
三菱重工、H-IIAロケット49号機による情報収集衛星レーダ8号機の打上げ延期について
Sept 9, 2024 16:00: JST
|
|
|
The 44th ASEAN Railway CEOs (ARCEOs') Conference Held in Bandung Achieving Sustainability through Digital Innovation
Sept 9, 2024 15:00 HKT/SGT
|
|
|
Brawijaya University Prof Develops Early Harvest, High-yield Corn Seeds
Sept 9, 2024 12:00 HKT/SGT
|
|
|
アリマンタシォン・クシュタール、セブン&アイ・ホールディングスからの回答に対する声明を発表
Sept 9, 2024 08:00: JST
|
|
|
Hong Kong Watch & Clock Fair, Salon de TIME conclude successfully
Sept 8, 2024 15:55 HKT/SGT
|
|
|
香港钟表展及国际名表荟萃圆满结束
Sept 8, 2024 15:45 HKT/SGT
|
|
|
|
More News >> |
|
|
|
|
|